Tata Consultancy Services Ltd — Q3 FY25
TCS reported Q3 FY25 revenue of INR 63,973 crore, up 5.6% YoY, with operating margin expanding 40 bps sequentially to 24.5%.
bullish
high
✓ Verified against BSE filing
Bear Cases vs Reality
The market's top concerns about TCS, tested against this quarter's numbers.
! Still alive
Revenue growth remains muted despite record TCV
The bear thesis
The market has been concerned that TCS's strong order book is not translating into commensurate revenue growth, as clients delay project starts and discretionary spending remains weak. This disconnect has persisted for multiple quarters.
What the numbers say
Revenue YoY growth in Q3 FY25 vs. TCV growth
Revenue grew 5.6% YoY in Q3 FY25, while TCV was a record $10.2 billion, up double-digit YoY.
Revenue growth of 5.6% YoY remains modest compared to the record TCV of $10.2 billion, indicating the conversion lag persists. Management's cautious commentary on discretionary spending and North America decline further supports this bear case.
Source: From analyst Q&A
! Still alive
North America revenue continues to decline
The bear thesis
North America revenue has been declining YoY for several quarters, and the market expected a recovery. However, the Q3 data shows continued weakness in this key market, which accounts for a large portion of revenue.
What the numbers say
North America revenue YoY growth in Q3 FY25
North America revenue declined 2.3% YoY in Q3 FY25.
The 2.3% YoY decline in North America revenue confirms that the weakness persists, with no sign of recovery. Management cited market-specific issues and strained client profitability, keeping this bear case alive.
Source: Flagged in previous quarter
! Still alive
Life sciences and healthcare recovery uncertain
The bear thesis
Life sciences and healthcare revenue declined 4.3% YoY in Q3, and management cited policy uncertainty in the US. The market is concerned that this vertical may not recover as expected.
What the numbers say
Life sciences and healthcare revenue YoY growth in Q3 FY25
Life sciences and healthcare revenue declined 4.3% YoY in Q3 FY25.
The 4.3% YoY decline confirms continued weakness in this vertical. Management's mention of policy uncertainty suggests no near-term recovery, keeping this bear case alive.
Source: Flagged in previous quarter
↓ Weakening
Margin improvement may be unsustainable due to BSNL tapering
The bear thesis
TCS reported a 24.5% margin in Q3, up 40 bps sequentially, but the BSNL contract is 70% complete and will taper from Q4. The market questions whether the margin improvement is sustainable given the loss of high-margin BSNL revenue.
What the numbers say
Operating margin in Q3 FY25 and guidance for Q4
Operating margin was 24.5% in Q3 FY25, with management aspiring to exit Q4 at 26%.
The 24.5% margin is an improvement, and management's aspiration to reach 26% by Q4 suggests confidence. However, the BSNL tapering could create a headwind, weakening but not killing the bear case.
Source: Market narrative